Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175042 | PMC |
| http://dx.doi.org/10.1016/S2214-109X(21)00213-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series.
Commun Med (Lond)
January 2025
Patient-Led Research Collaborative, Oakland, CA, USA.
Background: Prior case series suggest that a 5-day course of oral Paxlovid (nirmatrelvir/ritonavir) benefits some people with Long COVID, within and/or outside of the context of an acute reinfection. To the best of our knowledge, there have been no prior case series of people with Long COVID who have attempted longer courses of nirmatrelvir/ritonavir.
Methods: We documented a case series of 13 individuals with Long COVID who initiated extended courses (>5 days; range: 7.
Nucleocapsid Antibodies as an Optimal Serological Marker of SARS-CoV-2 Infection: A Longitudinal Study at the Thomayer University Hospital.
J Clin Lab Anal
January 2025
Department of Clinical Biochemistry, Thomayer University Hospital, Prague, Czech Republic.
Background: The longitudinal study was conducted over the initial 2 years of the COVID-19 pandemic, spanning from June 2020 to December 2022, in healthcare workers (HCWs) of the Thomayer University Hospital. A total of 3892 blood samples were collected and analyzed for total nucleocapsid (N) antibodies. The aim of the study was to evaluate the dynamics of N antibodies, their relationship to the PCR test, spike (S) antibodies, interferon-gamma, and prediction of reinfection with SARS-CoV-2.
View Article and Find Full Text PDFModeling COVID-19 dynamics in the Basque Country: characterizing population immunity profile from 2020 to 2022.
BMC Infect Dis
January 2025
Basque Center for Applied Mathematics, Bilbao, Bizkaia, Spain.
Background: COVID-19, caused by SARS-CoV-2, has spread globally, presenting a significant public health challenge. Vaccination has played a critical role in reducing severe disease and deaths. However, the waning of immunity after vaccination and the emergence of immune-escape variants require the continuation of vaccination efforts, including booster doses, to maintain population immunity.
View Article and Find Full Text PDFA generalised catalytic model to assess changes in risk for multiple reinfections with SARS-CoV-2.
PLoS One
January 2025
South African DSI-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.
Background: Monitoring trends in multiple infections with SARS-CoV-2, following several pandemic waves, provides insight into the biological characteristics of new variants, but also necessitates methods to understand the risk of multiple reinfections.
Objectives: We generalised a catalytic model designed to detect increases in the risk of SARS-CoV-2 reinfection, to assess the population-level risk of multiple reinfections.
Methods: The catalytic model assumes the risk of reinfection is proportional to observed infections and uses a Bayesian approach to fit model parameters to the number of nth infections among individuals that occur at least 90 days after a previous infection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!